FORM 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2004
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ______________ to
Commission file number 0-19777
DUSA Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
New Jersey 22-3103129
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
25 Upton Drive
Wilmington, Massachusetts 01887
(Address of principal executive offices)
(Zip Code)
(978) 657-7500
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 month (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
Indicate by check mark whether the registrant has filed all documents
and reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court.
Yes [ ] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date:
16,855,697 shares as of August 10, 2004
PART I.
ITEM 1. UNAUDITED FINANCIAL STATEMENTS
DUSA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JUNE 30, DECEMBER 31,
2004 2003
(UNAUDITED)
------------- ------------
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 30,057,306 $ 4,294,482
United States government securities 25,767,385 30,284,841
Accrued interest receivable 444,137 533,796
Accounts receivable 766,178 229,483
Inventory 891,280 712,831
Prepaids and other current assets 1,087,983 1,000,413
------------- ------------
TOTAL CURRENT ASSETS 59,014,269 37,055,846
Restricted cash 139,847 139,213
United States government securities - 3,250,940
Property and equipment, net 3,772,582 4,251,489
------------- ------------
TOTAL ASSETS $ 62,926,698 $ 44,697,488
============= ============
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $ 413,662 $ 859,282
Accrued payroll 658,527 796,618
Other accrued expenses 1,518,544 1,162,139
Current maturities of long-term debt - 270,000
Deferred revenue 323,939 129,900
------------- ------------
TOTAL CURRENT LIABILITIES 2,914,672 3,217,939
Long-term debt, net of current maturities - 1,247,500
------------- ------------
TOTAL LIABILITIES $ 2,914,672 $ 4,465,439
------------- ------------
COMMITMENTS AND CONTINGENCIES (NOTE 10)
SHAREHOLDERS' EQUITY
Capital Stock
Authorized: 100,000,000 shares; 40,000,000 shares designated as common
stock, no par, and 60,000,000 shares issuable in series or classes; and
40,000 junior Series A preferred shares. Issued and outstanding:
16,827,122 (2003: 13,966,247) shares of common stock, no par $ 124,523,928 $ 95,670,554
Additional paid-in capital 2,256,339 2,015,586
Accumulated deficit (67,507,522) (58,909,781)
Accumulated other comprehensive income 739,281 1,455,690
------------- ------------
TOTAL SHAREHOLDERS' EQUITY 60,012,026 40,232,049
------------- ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 62,926,698 $ 44,697,488
============= ============
See the accompanying Notes to the Condensed Consolidated Financial Statements.
2
DUSA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
(UNAUDITED) (UNAUDITED)
---------------------------- ----------------------------
2004 2003 2004 2003
------------ ------------ ------------ ------------
REVENUES
Product sales $ 2,176,028 $ 147,275 $ 3,431,713 $ 290,645
OPERATING COSTS
Cost of product sales and royalties 1,068,711 824,027 1,894,716 1,577,331
Research and development 1,577,294 1,448,600 3,265,060 2,964,991
Marketing and sales 1,699,145 532,978 3,066,603 1,063,490
General and administrative 2,402,546 1,679,750 4,577,793 3,155,021
------------ ------------ ------------ ------------
TOTAL OPERATING COSTS 6,747,696 4,485,355 12,804,172 8,760,833
------------ ------------ ------------ ------------
LOSS FROM OPERATIONS (4,571,668) (4,338,080) (9,372,459) (8,470,188)
OTHER INCOME
Interest income, net 375,581 526,964 774,718 1,093,099
------------ ------------ ------------ ------------
NET LOSS $ (4,196,087) $ (3,811,116) $ (8,597,741) $ (7,377,089)
============ ============ ============ ============
BASIC AND DILUTED NET LOSS PER
COMMON SHARE $ (.25) $ (.27) $ (.55) $ (.53)
============ ============ ============ ============
WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING 16,727,111 13,932,424 15,764,792 13,912,579
============ ============ ============ ============
See the accompanying Notes to the Condensed Consolidated Financial Statements.
3
DUSA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
SIX MONTHS ENDED JUNE 30,
2004 2003
(UNAUDITED) (UNAUDITED)
------------ -----------
CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net loss $ (8,597,741) $(7,377,089)
Adjustments to reconcile net loss to net cash used in operating
activities:
Amortization of premiums and accretion of discounts on United States
government securities available for sale, net 51,986 47,096
Depreciation and amortization expense 896,372 610,504
Issuance of common stock to consultants 240,753 75,000
Changes in other assets and liabilities impacting cash flows from
operations:
Restricted cash (634) (699)
Accrued interest receivable 89,659 85,459
Accounts receivable (536,695) (62,411)
Inventory (178,449) 151,672
Prepaids and other current assets (87,570) 237,459
Accounts payable (445,619) (230,295)
Accrued payroll and other accrued expenses 218,314 (741,300)
Deferred revenue 194,039 61,050
------------ -----------
NET CASH USED IN OPERATING ACTIVITIES (8,155,585) (7,143,554)
------------ -----------
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES
Proceeds from maturing United States government securities 7,000,000 8,000,000
Purchases of property and equipment (417,465) (172,904)
------------ -----------
NET CASH PROVIDED BY INVESTING ACTIVITIES 6,582,535 7,827,096
------------ -----------
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES
Issuance of common stock 28,462,500 -
Stock offering costs (200,202) -
Proceeds from exercise of options 591,076 -
Payments of long-term debt (1,517,500) (135,000)
------------ -----------
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 27,335,874 (135,000)
------------ -----------
NET INCREASE IN CASH AND CASH EQUIVALENTS 25,762,824 548,542
------------ -----------
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 4,294,482 6,926,713
------------ -----------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 30,057,306 $ 7,475,255
============ ===========
NON-CASH TRANSACTION
The Company issued 135,000 shares of its common stock in a private placement at
$11.00 per share as commission and non-refundable retainer to the placement
agent on March 2, 2004, and an additional 20,250 shares on April 14, 2004 with
respect to the exercise of the additional investment rights, for a total value
of $1,707,750.
See the accompanying Notes to the Condensed Consolidated Financial Statements.
4
1) BASIS OF PRESENTATION
The Condensed Consolidated Balance Sheet as of June 30, 2004, Condensed
Consolidated Statements of Operations for the three and six months ended June
30, 2004 and 2003, and Condensed Consolidated Statements of Cash Flows for the
six months ended June 30, 2004 and 2003 of DUSA Pharmaceuticals, Inc. (the
"Company" or "DUSA") have been prepared in accordance with accounting principles
generally accepted in the United States of America. These condensed consolidated
financial statements are unaudited but include all normal recurring adjustments,
which management of the Company believes to be necessary for fair presentation
of the periods presented. The results of the Company's operations for any
interim period are not necessarily indicative of the results of the Company's
operations for any other interim period or for a full year.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been condensed or omitted. These
condensed consolidated financial statements should be read in conjunction with
the Company's December 31, 2003 audited consolidated financial statements and
notes thereto. Certain amounts for 2003 have been reclassified to conform to the
current year presentation. Such reclassifications had no impact on the net loss
or shareholders' equity for any period presented.
2) UNITED STATES GOVERNMENT SECURITIES AVAILABLE FOR SALE
The Company's United States government securities available for sale
consist of securities of the United States government and its agencies, with
current yields, as of June 30, 2004, ranging from 3.70% to 7.59% and maturity
dates ranging from July 15, 2004 to September 24, 2007.
Accumulated other comprehensive income consists of net unrealized gains
on United States government securities available for sale, which is reported as
part of shareholders' equity in the Condensed Consolidated Balance Sheets.
3) INVENTORY
Inventory consisted of the following:
JUNE 30,
2004 DECEMBER 31,
(UNAUDITED) 2003
----------- -----------
Finished goods $347,876 $582,382
Work in process 396,852 -
Raw materials 146,552 130,449
-------- --------
$891,280 $712,831
======== ========
5
4) OTHER ACCRUED EXPENSES
Other accrued expenses consisted of the following:
JUNE 30,
2004 DECEMBER 31,
(UNAUDITED) 2003
---------- ----------
Research and development costs $ 49,736 $ 184,912
Marketing and sales costs 216,649 113,020
Product related costs 342,627 144,826
Legal and other professional fees 565,654 359,747
Employee benefits 178,117 189,051
Other expenses 165,761 170,583
---------- ----------
$1,518,544 $1,162,139
========== ==========
5) LONG-TERM DEBT
In May 2002, DUSA entered into a secured term loan promissory note
("Note") with Citizens Bank of Massachusetts to fund the construction of its
manufacturing facility and borrowed $1,900,000. Based on the terms of the Note,
at June 30th of each year DUSA could either continue to choose a LIBOR-based
rate at that time, execute a one-time conversion to a fixed rate loan, or repay
the loan balance. DUSA repaid the outstanding loan balance in June 2004. The
security interest in approximately $3,000,000 of the Company's United States
government securities that were pledged as collateral to secure the loan was
released.
6) SHAREHOLDERS' EQUITY
On February 27, 2004, the Company completed a private placement of
2,250,000 shares of its common stock at a purchase price of $11.00 per share,
resulting in gross proceeds of $24,750,000. The closing date of the private
placement was March 2, 2004. The Company also granted the investors the right to
purchase up to an aggregate of an additional 337,500 shares of common stock at
$11.00 per share. These additional investment rights were exercised on April 14,
2004, resulting in additional gross proceeds of $3,712,500. Offering costs
incurred as of June 30, 2004 in connection with the placement were $1,907,952,
of which $1,707,750 consisted of the placement agent's commission and
non-refundable retainer paid in the form of 135,000 shares of common stock
calculated at the offering price and an additional 20,250 shares issued with
respect to the exercise of the additional investment rights.
On March 18, 2004, the Company granted a total of 30,000 fully vested
options to three consultants on its Medical Advisory Board as compensation for
services. These options were valued at $240,753 in accordance with the fair
value-based method as required by Statement of Financial Accounting Standards
("SFAS") No. 123, "Accounting for Stock-Based Compensation," as amended by SFAS
No. 148, "Accounting for Stock-Based Compensation, Transition and Disclosure,"
and Emerging Issues Task Force ("EITF") No. 96-18, "Accounting for Equity
Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services,"
6
and recorded as part of research and development costs in the Condensed
Consolidated Statement of Operations.
7) ACCOUNTING FOR STOCK BASED COMPENSATION
SFAS No. 123, as amended by SFAS No. 148, addresses the financial
accounting and reporting standards for stock or other equity-based compensation
arrangements. The Company has elected to continue to use the intrinsic
value-based method to account for employee stock option awards under the
provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock
Issued to Employees," and to provide disclosures based on the fair value method
in the Notes to the Consolidated Financial Statements as permitted by SFAS No.
123, as amended by SFAS No. 148. Under the intrinsic value method, compensation
expense, if any, is recognized for the difference between the exercise price of
the option and the fair value of the underlying common stock as of a measurement
date. The measurement date is the time when both the number of shares and the
exercise price is known. Stock or other equity-based compensation for
non-employees must be accounted for under the fair value-based method as
required by SFAS No. 123, as amended by SFAS No. 148, and EITF No. 96-18, and
other related interpretations. Under this method, the equity-based instrument is
valued at either the fair value of the consideration received or the equity
instrument issued on the measurement date, which is generally the grant date.
The resulting compensation cost is recognized and charged to operations over the
service period, which is generally the vesting period.
7
As described above, the Company uses the intrinsic value method to
measure compensation expense associated with grants of stock options to
employees. Had the Company used the fair value method to measure compensation,
the Company's pro forma net loss and pro forma net loss per common share for the
three and six months ending June 30, 2004 and 2003 would have been as follows:
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
(UNAUDITED) (UNAUDITED)
------------------------------ -------------------------------
2004 2003 2004 2003
------------- ------------- -------------- -------------
NET LOSS
As reported $ (4,196,087) $ (3,811,116) $ (8,597,741) $ (7,377,089)
Effect on net loss if fair value method had
been used (779,453) (543,712) (1,496,598) (1,130,921)
------------- ------------- -------------- -------------
Proforma $ (4,975,540) $ (4,354,828) $ (10,094,339) $ (8,508,010)
============= ============= ============== =============
BASIC AND DILUTED NET LOSS PER COMMON SHARE
As reported $ (.25) $ (.27) $ (.55) $ (.53)
Effect on net loss per common share if fair
value method had been used (.05) (.04) (.09) (.08)
------------- ------------- -------------- -------------
Proforma $ (.30) $ (.31) $ (.64) $ (.61)
============= ============= ============== =============
8) BASIC AND DILUTED NET LOSS PER COMMON SHARE
Basic net loss per common share is based on the weighted average number
of shares outstanding during each period. Stock options and warrants are not
included in the computation of the weighted average number of shares outstanding
for dilutive net loss per common share during each of the periods presented in
the Condensed Consolidated Statements of Operations, as the effect would be
antidilutive. For the periods ended June 30, 2004 and 2003, such potentially
dilutive securities totaling approximately 3,083,000 and 2,705,000 shares,
respectively, have been excluded from the computation of diluted net loss per
common share.
8
COMPREHENSIVE LOSS
For the three and six months ended June 30, 2004 and 2003,
comprehensive loss consisted of the following:
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
(UNAUDITED) (UNAUDITED)
-------------------------- --------------------------
2004 2003 2004 2003
----------- ----------- ----------- -----------
NET LOSS $(4,196,087) $(3,811,116) $(8,597,741) $(7,377,089)
Change in net unrealized gains on United
States securities available for sale (568,750) (120,333) (716,409) (367,331)
----------- ----------- ----------- -----------
COMPREHENSIVE LOSS $(4,764,837) $(3,931,449) $(9,314,150) $(7,744,420)
=========== =========== =========== ===========
10) COMMITMENTS AND CONTINGENCIES
Legal Matters - On April 12, 2002, the Company received notice that one
of the patents licensed to the Company by PARTEQ Research & Development
Innovations, the technology transfer arm of Queen's University at Kingston,
Ontario was being challenged by PhotoCure ASA. PhotoCure ASA filed a lawsuit in
Australia alleging that Australian Patent No. 624985, which is one of the
patents relating to the Company's 5-aminolevulinic acid technology, was invalid.
As a consequence of this action, Queen's University assigned the Australian
patent to the Company so that DUSA could participate directly in this
litigation. The Company filed a response setting forth its defenses, and a
related countersuit alleging that certain activities of PhotoCure and its
marketing partner, Galderma S.A., infringe the patent. The final hearing in the
Federal Court of Australia was held in April 2004, and a decision is expected in
late 2004. Each party has the right to appeal within approximately one month
following the Court's decision. The Company is unable to predict the outcome of
the case at this time.
In December 2003, the Company was served with a complaint filed in the
State of Michigan Circuit Court for the County of Oakland alleging that DUSA's
BLU-U(R) caused the plaintiff to suffer a seizure during the performance of her
duties as an office assistant. The complaint names Berlex Laboratories, Inc., a
subsidiary of the Company's former marketing partner, as another defendant. The
case has been removed to the U.S. District Court for the Eastern District of
Michigan Southern Division. The damages are unspecified. The Company has filed
its answer denying the claims, and Berlex has requested indemnification from
the Company under the terms of the Company's former agreement with Schering AG,
Berlex's parent. Currently, the Company has declined to indemnify Berlex. While
it is not possible to predict or determine the outcome of this action, the
Company believes that the costs associated with all such matters will not have a
material adverse effect on its
9
consolidated financial position or liquidity, but could possibly be material to
the consolidated results of operations in any one period to the extent costs are
not covered by DUSA's insurance.
11) THIRD-PARTY CANADIAN MARKETING AND DISTRIBUTION AGREEMENT
On March 31, 2004, DUSA signed an exclusive Canadian marketing and
distribution agreement for the Kerastick(R) and BLU-U(R) with Coherent-AMT Inc.
("Coherent"), a leading Canadian medical device and laser distribution company.
Coherent began marketing the BLU-U(R) for moderate inflammatory acne in April
2004 and the Kerastick(R) for the treatment of non-hyperkeratotic actinic
keratoses, or AKs, in June 2004, following receipt of the applicable regulatory
approval from Health Canada. The agreement has a three-year term, which can be
automatically renewed for additional one-year terms, unless either party
notifies the other party prior to a term expiration that it does not intend to
renew the agreement. In addition, during the initial three-year term, either
party may terminate the agreement earlier by providing formal written notice of
its intention to do so at least 90 days in advance of each anniversary of the
effective date, or in the event that the other party shall have materially
breached any of its obligations in the agreement. DUSA recognizes product sales
when Coherent sells the Kerastick(R) and the BLU-U(R) to the end-user, as the
price is fixed and final at that point.
12) AMENDED/RESTATED PURCHASE AND SUPPLY AGREEMENT
On June 21, 2004, DUSA signed an Amended and Restated Purchase and
Supply Agreement with National Biological Corporation ("NBC"), the manufacturer
of its BLU-U(R) light source. This agreement provides for the elimination of
certain exclusivity clauses, permits DUSA to order on a purchase order basis
without minimums, and other modifications of the original agreement providing
both parties greater flexibility related to the development and manufacture of
light sources, and the associated technology within the field of PDT. DUSA paid
$110,000 to NBC upon execution of the agreement which will be amortized over
the remaining term of the agreement, expiring November 5, 2008.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
OVERVIEW
DUSA is a pharmaceutical company engaged primarily in the research,
development, and marketing of a drug named 5-aminolevulinic acid, or ALA, which
is used in combination with appropriate light devices in order to detect or
treat a variety of medical conditions. The trademark for our brand of ALA is
Levulan(R). When Levulan(R) is used and followed with exposure to light to
produce a therapeutic effect, the technology is called photodynamic therapy, or
PDT. When Levulan(R) is used and followed with exposure to light to detect
medical conditions, the technology is called photodetection, or PD. Our
products, which were launched in September 2000 in the United States, are
Levulan(R) 20% topical solution using our Kerastick(R) brand applicator, and our
BLU-U(R) brand light unit. Our products are used together to provide PDT for the
treatment of non-hyperkeratotic actinic keratoses, or AKs, of the face or scalp.
In addition, DUSA received market
10
clearance from the United States Food and Drug Administration ("FDA") in
September 2003 to market the BLU-U(R) without Levulan(R) for the treatment of
moderate inflammatory acne vulgaris.
Marketing and sales activities since the October 2003 launch of our
sales force have resulted in significant additional expenses; however, the
impact on sales has been positive. Kerastick(R) unit sales to end-users were
17,910 for the three months ended June 30, 2004, including 1,908 sold by
Coherent-AMT, our Canadian marketing and distribution partner. This compared to
12,054 Kerastick(R) units sold during the three months ended March 31, 2004 and
1,914 during the three months ended June 30, 2003, neither of which included any
Canadian sales. The number of BLU-U(R) units placed in doctors' offices during
the quarter also increased significantly, by 241, to 775 units, including 58
placed in Canada, compared with 534 in place at March 31, 2004 and 323 in
physician offices at June 30, 2003.
Although the costs related to the addition of our sales force and
related marketing activities are currently greater than the gross margin
generated from the increased sales, we are encouraged with the ongoing increases
in sales. We are continuing our efforts to penetrate the market through
expanding our sales coverage in key geographic locations. As of June 30, 2004,
we reached our second quarter target of 16 sales representatives and area
managers. Since then, we decided to increase the size of our direct sales force
to approximately 23 during 2004, and as of August 10, 2004, the sales force
total stood at 21. We expect to continue to incur operating losses until sales
of our products increase substantially above the current levels. At this time,
our core objectives include focusing on increasing sales in the United States,
conducting clinical trials to treat acne vulgaris and photodamaged skin, which,
if successful, could lead to additional regulatory approvals, and making plans
to advance development of Levulan(R) PDT for the treatment of dysplasia in
patients with Barrett's esophagus. In addition, we continue to support
independent investigator trials to advance research in the use and applicability
of Levulan(R) PDT for indications in dermatology.
On June 21, 2004, DUSA signed an Amended and Restated Purchase and
Supply Agreement with National Biological Corporation ("NBC"), the manufacturer
of its BLU-U(R) light source. This agreement eliminated certain exclusivity
clauses, permits DUSA to order on a purchase order basis without minimums, and
made other modifications to the original agreement providing both parties
greater flexibility related to the development and manufacture of light sources,
and the associated technology within the field of PDT. DUSA paid $110,000 to NBC
upon execution of the agreement which will be amortized over the remaining term
of the agreement, expiring November 5, 2008. As of June 30, 2004, DUSA had 775
BLU-U(R) light sources placed in physician's offices with approximately 160
light units remaining in inventory. This declining level of remaining inventory
is due to the higher than anticipated demand for the BLU-U(R) during the first
six months of 2004. The Company is evaluating its options with respect to
ordering more BLU-U(R) light units, and/or developing alternative light sources.
We could experience a backlog once our current BLU-U(R) inventory is depleted,
so until a new supply of light sources is available, BLU-U(R) revenues are
expected to be limited by supply constraints. In addition, growth of
Kerastick(R) units could be adversely affected by limited BLU-U(R) sales, though
we believe this effect should not be significant.
11
On February 24, 2004, DUSA reacquired the rights to the aminolevulinic
acid (Levulan(R)) technology for Canada held by Draxis Health Inc. ("Draxis"),
DUSA's former parent. These rights were initially assigned to Draxis in 1991 at
the time of the original licensing of the patents underlying our Levulan(R) PDT
platform from PARTEQ Research and Development Innovations, the licensing arm of
Queen's University, Kingston, Ontario. DUSA and Draxis terminated the assignment
and DUSA agreed to pay to Draxis an upfront fee and an ongoing royalty on sales
of the Levulan(R) Kerastick(R) in Canada over a five year term. In addition, on
March 31, 2004 DUSA signed an exclusive marketing and distribution agreement for
Canada with Coherent-AMT, a leading Canadian medical device and laser
distribution company. Coherent-AMT began marketing the BLU-U(R) for moderate
inflammatory acne upon entering our agreement and the Kerastick(R) in June 2004
for the treatment of non-hyperkeratotic actinic keratoses, or AKs, following
receipt of regulatory approval from Health Canada.
In February 2004, DUSA commenced commercial production of the
Levulan(R) Kerastick(R) at its Wilmington, Massachusetts manufacturing facility.
Production continued during the current quarter based upon the anticipated
demand for the Kerastick(R). During the current quarter, we commenced the
distribution of the initial commercial product produced at our manufacturing
facility.
On February 27, 2004, DUSA entered into definitive agreements with
certain institutional and other accredited investors for the private placement
of 2,250,000 shares of its common stock at a purchase price of $11.00 per share,
resulting in gross proceeds to DUSA of $24,750,000. The closing date of the
private placement was March 2, 2004. DUSA also issued Additional Investment
Rights providing the investors with the right to purchase up to an aggregate of
an additional 337,500 shares of common stock at $11.00 per share. All of the
Additional Investment Rights were exercised on April 14, 2004. Offering costs
incurred as of June 30, 2004 in connection with the placement were $1,908,000,
of which $1,708,000 consisted of the placement agent's commission and
non-refundable retainer paid in the form of 135,000 shares of common stock and
an additional 20,250 shares issued with respect to the exercise of the
Additional Investment Rights, all of which were calculated at the offering
price. DUSA will use the proceeds from the sale of the securities to expand its
sales force and for general working capital purposes, including research and
development activities.
DUSA has devoted its resources primarily to fund research and
development in order to advance the Levulan(R) PDT/PD technology platform and,
as a result, we have experienced significant operating losses. As of June 30,
2004, we had an accumulated deficit of approximately $67,508,000. Achieving our
goal of becoming a profitable operating company is dependent upon acceptance of
our therapy by the medical and consumer constituencies and our ability to
develop new products.
DUSA has continued to support efforts to improve reimbursement levels
to physicians. Some physicians have suggested that current reimbursement levels
still do not fully reflect the required efforts to routinely employ our therapy
in their practices. We believe that this issue has adversely affected the
economic competitiveness of our products with other AK therapies and has
hindered the adoption of our therapy. However, we continue to work to educate
the major private insurance carriers about our AK therapy, and as of June 30,
2004, several major private insurers have approved coverage. We believe that due
to these efforts, along with our education and marketing programs,
12
and increased interest in other uses for our products, more widespread adoption
by the medical community will occur over time.
We have been encouraged by the positive response from many physicians
and patients who have used our therapy, but we recognize that we have to
continue to demonstrate the clinical value of our unique therapy, and the
related product benefits as compared to other well-established conventional
therapies, in order for the medical community to accept our products on a large
scale. While our financial position is strong, we cannot predict when product
sales may offset the costs associated with these efforts. We are aware that some
physicians have been using Levulan(R) with the BLU-U(R), and with light devices
manufactured by other companies, for uses other than our FDA-approved use. While
we are not permitted to market our products for so-called "off-label" uses,
these activities are positively affecting the sales of our products.
As of June 30, 2004, DUSA's staff included 56 full-time employees and 2
part-time employees as compared to 50 full-time employees and 1 part-time
employee at the end of 2003. These include marketing and sales, production,
maintenance, customer support, and financial operations personnel, as well as
those who support research and development programs for dermatology and internal
indications. We expect to continue to increase our staff in 2004 as we focus on
sales, marketing activities and customer support associated with our AK
products, and research and development programs for dermatology and internal
indications.
CRITICAL ACCOUNTING POLICIES
Our accounting policies are disclosed in Note 2 to the Notes to the
Consolidated Financial Statements in our Annual Report on Form 10-K for the year
ended December 31, 2003. Since all of these accounting policies do not require
management to make difficult, subjective or complex judgments or estimates, they
are not all considered critical accounting policies. We have discussed these
policies and the underlying estimates used in applying these accounting policies
with our audit committee. We consider the following policies and estimates to be
critical to our financial statements.
REVENUE RECOGNITION - Revenues on product sales are recognized when
persuasive evidence of an arrangement exists, the price is fixed and final,
delivery has occurred, and there is reasonableness of collection. Product sales
made through distributors who have a general right of return of product have
been recorded as deferred revenue until the product is sold by our distributors
to the end user. Although we make every effort to assure the reasonableness of
our estimates, significant unanticipated changes in our estimates due to
business, economic, or industry events could have a material impact on our
results of operations.
INVENTORY - Inventories are stated at the lower of cost or market. Cost
is determined using the first-in, first-out method. Inventories are continually
reviewed for slow moving, obsolete or excess items. Inventory items identified
as slow-moving are evaluated to determine if an adjustment is required.
Additionally, our industry is characterized by regular technological
developments that could result in obsolete inventory. Although we make every
effort to assure the reasonableness of
13
our estimates, any significant unanticipated changes in demand, technological
development, or significant changes to our business model could have a
significant impact on the value of our inventory and our results of operations.
We use sales projections to estimate the appropriate level of inventory that
should remain on the Condensed Consolidated Balance Sheet. Management believes
that the level of remaining Kerastick(R) inventory is reasonable in light of our
current sales forecasts. However, if we do not order more BLU-U(R) units from
our supplier or develop an alternative BLU-U(R) light device, we could
experience a shortage of these light devices.
VALUATION OF LONG-LIVED AND INTANGIBLE ASSETS - We review long-lived
assets for impairment whenever events or changes in business circumstances
indicate that the carrying amount of assets may not be fully recoverable or that
the useful lives of these assets are no longer appropriate. Factors considered
important which could trigger an impairment review include significant changes
relative to: (i) projected future operating results; (ii) the use of the assets
or the strategy for the overall business; (iii) business collaborations; and
(iv) industry, business, or economic trends and developments. Each impairment
test is based on a comparison of the undiscounted cash flow to the recorded
value of the asset. If it is determined that the carrying value of long-lived or
intangible assets may not be recoverable based upon the existence of one or more
of the above indicators of impairment, the asset is written down to its
estimated fair value on a discounted cash flow basis. At June 30, 2004, our
total property, plant and equipment had a carrying value of $3,773,000,
including $2,048,000 associated with our manufacturing facility, which received
FDA approval in July 2003 and began inventory production in February 2004. We
had no intangible assets recorded as of June 30, 2004 and December 31, 2003.
STOCK-BASED COMPENSATION - We have elected to continue to use the
intrinsic value-based method to account for employee stock option awards under
the provisions of Accounting Principles Board Opinion No. 25, and to provide
disclosures based on the fair value method in the Notes to the Condensed
Consolidated Financial Statements as permitted by Statement of Financial
Accounting Standards ("SFAS") No. 123, "Accounting for Stock Compensation," as
amended by SFAS No. 148, "Accounting for Stock-Based Compensation, Transition
and Disclosure". Stock or other equity-based compensation for non-employees is
accounted for under the fair value-based method as required by SFAS No. 123 and
Emerging Issues Task Force ("EITF") No. 96-18, "Accounting for Equity
Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services" and other related interpretations.
Under this method, the equity-based instrument is valued at either the fair
value of the consideration received or the equity instrument issued on the date
of grant. The resulting compensation cost is recognized and charged to
operations over the service period, which, in the case of stock options, is
generally the vesting period. As we utilize stock and stock options as one means
of compensating employees, consultants, and others, a change in accounting for
stock-based compensation could, under certain circumstances, result in an
adverse material effect on our results of operations, but would not affect cash
flows.
14
RESULTS OF OPERATIONS
REVENUES - Total revenues for the three and six months ended June 30,
2004 were $2,176,000 and $3,432,000, respectively, as compared to $147,000 and
$291,000 in the same periods in 2003, and were comprised of the following:
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
(UNAUDITED) (UNAUDITED)
-------------------------- --------------------------
2004 2003 2004 2003
---------- -------- ---------- --------
PRODUCT SALES REVENUES
Direct Kerastick(R) sales to
physicians $1,304,000 $147,000 $2,200,000 $291,000
BLU-U(R) sales to physicians 872,000 - 1,232,000 -
---------- -------- ---------- --------
Total product sales $2,176,000 $147,000 $3,432,000 $291,000
========== ======== ========== ========
The increase in 2004 product sales reflects sales to physicians of
17,910 and 29,964 Kerastick(R) units for the three and six months ended June 30,
2004, respectively, as compared to 1,914 and 3,756 Kerastick(R) units for the
comparable 2003 periods. The increase in product revenues also reflects an
increase in the BLU-U(R) units placed in physician's offices to 775 units as of
June 30, 2004, up from 406 units at December 31, 2003.
On March 31, 2004, DUSA signed an exclusive marketing and distribution
agreement for the Kerastick(R) and BLU-U(R) in Canada with Coherent-AMT Inc.
("Coherent"), a leading Canadian medical device and laser distribution company.
Following receipt of regulatory approval from Health Canada, Coherent began
marketing the BLU-U(R) for moderate inflammatory acne in April 2004, and the
Kerastick(R) for the PDT treatment of non-hyperkeratotic actinic keratoses, or
AKs, in June 2004. DUSA recognizes product sales when Coherent sells the
Kerastick(R) and/or the BLU-U(R) to the end-user, as the price is fixed and
final at that point. Product sales for the three and six months ended June 30,
2004 included 1,908 Kerastick(R) units and 58 BLU-U(R) units placed in Canada,
and representing revenue of $100,000 and $183,000, respectively.
The increase of both Kerastick(R) and BLU-U(R) sales in the United
States is a result of the efforts of our sales force, which we launched in
October 2003, and includes sales generated at dermatology conferences including
the American Academy of Dermatology ("AAD") annual meeting in February 2004,
which is the largest and most prestigious annual dermatology conference. In
addition, the increase in BLU-U(R) placements is caused, in part, by our ability
to sell the BLU-U(R) to physicians as a stand alone device for the treatment of
moderate inflammatory acne vulgaris since September 2003, following FDA
clearance.
Although the level of Kerastick(R) sales to end-users for 2004 is
higher than the level in the prior year, Kerastick(R) sales must continue to
increase significantly in order for DUSA to become profitable. To reach that
goal, we have increased our sales force's geographic reach, and we will continue
to participate in medical conferences throughout the year. Due to the potential
for elective
15
procedures to decline during the summer months, we do not expect sales for the
third quarter of 2004 to increase at the same rate that we experienced during
the last three quarters. In addition, we do not expect to generate the same
level of sales from conferences as we did in the first two fiscal quarters.
However, due to the increasing number of sales representatives, and the
increasing acceptance of our therapy, we do expect that sales levels will
increase during the fourth quarter of 2004 and in 2005. See "Results of
Operations-Marketing and Sales Costs".
COST OF PRODUCT SALES AND ROYALTIES - Cost of product sales and
royalties for the three and six months ended June 30, 2004 were $1,069,000 and
$1,895,000, respectively, as compared to $824,000 and $1,577,000 in the
comparable 2003 periods. A summary of the components of cost of product sales
and royalties is provided below:
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
(UNAUDITED) (UNAUDITED)
------------------------------------- ---------------------------------------
INCREASE INCREASE
2004 2003 (DECREASE) 2004 2003 (DECREASE)
---------- -------- --------- ---------- ---------- ---------
Product costs including
internal costs (e.g.
customer service,
quality assurance,
purchasing, depreciation,
amortization and
other product support
operations) assigned to
$ 305,000 $697,000 $(392,000) support products (1) $ 700,000 $1,351,000 $(651,000)
Direct Kerastick(R) product
346,000 37,000 309,000 costs 579,000 73,000 506,000
Costs incurred to ship,
install and service the
BLU-U(R) in physicians
354,000 71,000 283,000 offices (2) 516,000 117,000 399,000
64,000 19,000 45,000 Royalty and supply fees (3) 100,000 36,000 64,000
---------- -------- --------- ---------- ---------- ---------
Total cost of product sales and royalties
$1,069,000 $824,000 $ 245,000 $1,895,000 $1,577,000 $ 318,000
========== ======== ========= ========== ========== =========
(1) The decrease in product costs for 2004 primarily reflects the
capitalization of labor and overhead associated with the start of
Kerastick(R) production in our facility. These costs were expensed in the
prior year due to the absence of production.
(2) Although there were direct BLU-U(R) product sales in 2004, there were no
related direct BLU-U(R) product costs as these units had a zero book value
due to inventory impairment charges recorded during 2002.
(3) Royalty and supply fees include fees paid to our licensor, PARTEQ Research
and Development Innovations, the licensing arm of Queen's University,
Kingston, Ontario, and in 2004 amortization of an upfront fee and a
royalty paid to Draxis, DUSA's former parent, on sales of the Levulan(R)
Kerastick(R) in Canada.
RESEARCH AND DEVELOPMENT COSTS - Research and development costs for the
three and six month periods ended June 30, 2004 were $1,577,000 and $3,265,000,
respectively, as compared to
16
$1,449,000 and $2,965,000 in the same periods in 2003. These increases reflect
the preparation work associated with initiating the Phase II photodamaged skin
trial, protocol finalization for our acne trial, and the start of our Phase II
pilot study for Barrett's esophagus offset, in part, by lower third-party
expenditures for our FDA mandated Phase IV clinical study of the long-term
efficacy of the Kerastick(R). This FDA mandated Phase IV study was completed in
late 2003 and we incurred only limited costs to file the final report with the
FDA in 2004. We have concentrated our dermatology development program on
indications that use our approved Kerastick(R). Based on market research that
was completed in 2003, we have moved forward with our Phase II clinical studies
for use of Levulan(R) PDT in photodamaged skin and moderate to severe acne
vulgaris. We initiated the photodamaged skin study during the second quarter of
2004 based on the Investigational New Drug application which was cleared by the
FDA. Subject to ongoing discussions with the FDA, we expect to initiate a Phase
II study on Levulan(R) PDT for the treatment of acne vulgaris during the third
quarter of 2004. In addition, DUSA is evaluating whether to develop an
alternative BLU-U(R) light device. We expect to incur total research and
development costs of approximately $6,500,000 to $7,500,000 during 2004 due
primarily to initiating these studies; however, this could increase by
approximately $2,000,000 if we decide to develop the new light source.
DUSA has also been following patients who completed Phase I/II studies
in the treatment of high-grade and low-grade dysplasia associated with Barrett's
esophagus. In preparation for new Phase II clinical trials, we have initiated a
small single-center pilot Phase II clinical trial using DUSA's new proprietary
endoscopic light delivery device for the treatment of high-grade dysplasia
associated with Barrett's Esophagus. However, currently, we do not plan to fund
other Phase II or III clinical trials for this indication on our own. Therefore,
we are seeking a strategic partner or similar collaboration to advance the
development of our treatment for Barrett's esophagus dysplasia. There can be no
assurance that we will be able to consummate any collaboration on terms
acceptable to us.
In addition, the current six month period includes compensation of
$241,000 for 30,000 fully vested stock options issued to three consultants for
services.
MARKETING AND SALES COSTS - Marketing and sales costs for the three and
six month periods ended June 30, 2004 were $1,699,000 and $3,067,000,
respectively, as compared to $533,000 and $1,063,000 in the comparable periods
in 2003. These increases were mainly attributable to the launch of our direct
sales force in October 2003 and related marketing and sales activities. As of
June 30, 2004, our sales force was comprised of 16 direct representatives and
various independent representatives in key target markets. We anticipate that
the level of marketing and sales expenses and related support functions will
continue to increase during the remainder of 2004 as we expand our sales
capacity.
GENERAL AND ADMINISTRATIVE COSTS - General and administrative costs for
the three and six month periods ended June 30, 2004 were $2,403,000 and
$4,578,000, respectively, as compared to $1,680,000 and $3,155,000 in the
comparable periods in 2003. These increases were mainly attributable to higher
legal expenses amounting to $1,331,000 and $2,531,000 during the current
17
three and six month periods, as compared to $903,000 and $1,586,000 in the
comparable 2003 periods, due primarily to patent litigation costs.
In April 2002, DUSA received a copy of a notice issued by PhotoCure ASA
to Queen's University at Kingston, Ontario, alleging that Australian Patent No.
624985, which is one of the patents licensed by PARTEQ to us, relating to ALA
technology, is invalid. As a consequence of this action, Queen's University
assigned the Australian patent to us so that we could participate directly in
this litigation. We filed an answer setting forth our defenses and a related
countersuit alleging that certain activities of PhotoCure and its marketing
partner, Galderma S.A., infringe the patent. The final hearing in the Federal
Court of Australia was held in April 2004, and we expect that the Court's
decision will be rendered in late 2004. We are unable to predict the outcome at
this time. However, should PhotoCure prevail in either part of the case, i.e.
the Court finds that (i) our patent is invalid, or (ii) the patent is valid, but
PhotoCure's product does not infringe the patent, PhotoCure will be able to
market its product in Australia. Each party has the right to appeal within
approximately one month of the Court's decision.
In December 2003, DUSA was served with a complaint filed in the State
of Michigan Circuit Court for the County of Oakland alleging that DUSA's
BLU-U(R) caused the plaintiff to suffer a seizure during the performance of her
duties as an office assistant. The complaint names Berlex Laboratories, Inc., a
subsidiary of our former marketing partner, as another defendant. The damages
are unspecified. The case has been removed to the U.S. District Court, Eastern
District of Michigan, Southern Division. We have filed our answer denying the
claims. Berlex has requested indemnification from DUSA under the terms of the
Company's former agreement with Schering AG, Berlex's parent. Currently, DUSA
has declined to indemnify Berlex. While it is not possible to predict or
determine the outcome of this action, we believe that the costs associated with
all such matters will not have a material adverse effect on its consolidated
financial position or liquidity but could possibly be material to the
consolidated results of operations in any one period to the extent costs are not
covered by DUSA's insurance.
It is expected that legal expenses will decline during the second half
of 2004 unless we enter into any additional significant legal activities, as we
await a decision from the Court in Australia.
OTHER INCOME, NET - Other income for the three and six month periods
ended June 30, 2004 was $376,000 and $775,000, as compared to $527,000 and
$1,093,000 in the comparable 2003 periods. These decreases were attributable to
a reduction in our average investable cash balances during 2003 and early 2004,
as we used cash to support our operating activities. With the addition of the
proceeds from the private placement in March 2004, interest income will
initially increase and then may decline, depending on the direction of interest
rates and as our investable cash balances are used to support our operating
activities. During the three and six month periods ended June 30, 2004, we
incurred interest expense of $9,000 and $20,000 on borrowings associated with
the construction of our Kerastick(R) manufacturing facility as compared to
$17,000 and $34,000 in 2003, which was capitalized in property and equipment in
the Condensed Consolidated Balance Sheet as of June 30, 2003.
18
NET LOSSES - For the three and six months ended June 30, 2004, we
incurred net losses of $4,196,000, or $0.25 per share, and $8,598,000, or $0.55
per share, respectively, as compared to net losses of $3,811,000, or $0.27 per
share, and $7,377,000, or $0.53 per share, for the comparable periods in 2003.
Net losses are expected to continue until product sales to physicians offset the
cost of our sales force and marketing initiatives, and the costs for other
business support functions.
LIQUIDITY AND CAPITAL RESOURCES
DUSA is in a strong cash position to continue to fund increased
Levulan(R) PDT sales and marketing expenses and current research and development
activities for its Levulan(R) PDT/PD platform. At June 30, 2004, we had
approximately $55,965,000 of total cash resources comprised of $30,057,000 of
cash and cash equivalents, United States government securities totaling
$25,767,000, and restricted cash of $140,000. All of our United States
government securities are classified as available for sale. As of June 30, 2004,
these securities had yields ranging from 3.70% to 7.59% and maturity dates
ranging from July 15, 2004 to September 24, 2007.
On February 27, 2004, DUSA completed a private placement of 2,250,000
shares of its common stock at a purchase price of $11.00 per share resulting in
gross proceeds of $24,750,000. We also granted the investors the right to
purchase up to an aggregate of an additional 337,500 shares of common stock at
$11.00 per share, which were exercised on April 14, 2004, resulting in
additional proceeds of $3,712,500. Offering costs incurred as of June 30, 2004
in connection with the placement were $1,907,000, of which $1,708,000 consisted
of the placement agent's commission and non-refundable retainer paid in the form
of 135,000 shares of common stock and an additional 20,250 shares issued with
respect to the exercise of the additional investment rights all of which were
calculated at the offering price.
As of June 30, 2004, working capital (total current assets minus total
current liabilities) was $56,100,000 as compared to $33,838,000 as of December
31, 2003. Total current assets increased $21,958,000 in 2004 due primarily to
the gross proceeds received from the private placement of $28,463,000, offset by
the use of $8,156,000 of cash and cash equivalents to support our operating
activities.
As of June 30, 2004, DUSA had current liabilities of $2,915,000, as
compared to $3,218,000 as of December 31, 2003. This decrease is due in part to
the repayment of debt in June 2004 with proceeds from the private placement. In
May 2002, we entered into a secured term loan promissory note ("Note") with
Citizens Bank of Massachusetts to fund the construction of our manufacturing
facility and borrowed $1,900,000. DUSA repaid the outstanding loan balance in
June 2004. The security interest in approximately $3,000,000 of our United
States government securities that were being pledged as collateral to secure the
loan was released.
DUSA believes that we have sufficient capital resources to proceed with
its current programs for Levulan(R) PDT and to fund operations and capital
expenditures for the foreseeable future. We have invested our funds in liquid
investments so that we will have ready access to these cash reserves
19
for funding our needs on a short-term and long-term basis.
DUSA may also seek to expand or enhance its business by using resources
to acquire businesses, new technologies, or products, especially in
dermatology-related areas. For the remainder of 2004, we are focusing primarily
on increasing sales of the Levulan(R) Kerastick(R) and the BLU-U(R).
DUSA has no off-balance sheet financing arrangements other than its
operating leases.
CONTRACTUAL OBLIGATIONS AND OTHER COMMERCIAL COMMITMENTS
In May 2002, DUSA entered into a secured term loan promissory note
("Note") with Citizens Bank of Massachusetts to fund the construction of its
manufacturing facility and borrowed $1,900,000. DUSA repaid the outstanding loan
balance in June 2004. The security interest in approximately $3,000,000 of our
United States government securities that were being pledged as collateral to
secure the loan was released.
On June 21, 2004, DUSA signed an Amended and Restated Purchase and
Supply Agreement with National Biological Corporation ("NBC"), the manufacturer
of its BLU-U(R) light source. This agreement eliminated certain exclusivity
clauses, permits the acquisition of light sources on a purchase order basis and
made other modifications to the original agreement providing both parties
greater flexibility related to the development and manufacture of light sources,
and the associated technology within the field of PDT. DUSA paid $110,000 to NBC
upon execution of the agreement which will be amortized over the term of the
agreement, expiring November 5, 2008.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
There have been no recently issued accounting pronouncements that have
a material impact on our financial reporting other than those presented in our
Annual Report on Form 10-K for the year ended December 31, 2003.
INFLATION
Although inflation rates have been comparatively low in recent years,
inflation is expected to apply upward pressure on our operating costs. We have
included an inflation factor in our cost estimates. However, the overall net
effect of inflation on our operations is expected to be minimal.
20
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK
DUSA holds fixed income United States government securities that are
subject to interest rate market risks. However, we do not believe that the risk
is material as we make our investments in relatively short-term instruments and
we strive to match the maturity dates of these instruments to our cash flow
needs. A ten percent decline in the average yield of these instruments would not
have a material effect on our results of operations or cash flows.
ITEM 4. CONTROLS AND PROCEDURES
DUSA carried out an evaluation, under the direction of its Chief
Executive Officer and Chief Financial Officer, of the effectiveness of the
design and operation of its disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, the
Chief Executive Officer and Chief Financial Officer concluded that our
disclosure controls and procedures were effective as of June 30, 2004.
There have been no changes in our internal control over financial
reporting that occurred during the quarter ended June 30, 2004 that have
materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.
FORWARD-LOOKING STATEMENTS
This report, including the Management's Discussion and Analysis,
contains various "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933 which represent our expectations or beliefs
concerning future events, including, but not limited to statements regarding the
outcome of litigation in Australia and Michigan and their respective potential
impact on DUSA's financial condition, management's goal of becoming profitable,
DUSA's current core objectives, intentions not to order additional BLU-Us(R),
intention to launch an alternative light device for the treatment of acne and
the costs related thereto, the use of proceeds from DUSA's sale of securities,
beliefs regarding adoption of our therapy, expectations regarding rates of sales
increases, expectations to pursue research of Barrett's Esophagus therapy,
expectations for continuing operating losses, expectations for acquiring new
businesses, technologies or products, expectations of inflation affecting
operating costs, expectations of market risk affecting DUSA's investments,
effects of unanticipated changes in estimates, technology and forecasts, belief
concerning reasonableness of inventory values, factors which could trigger
impairment review, effect of an accounting change for stock-based compensation,
expectations for increased marketing and sales costs, expectations regarding
future levels of legal fees, expectations regarding levels of interest income
and net losses, requirements of cash resources, and potential impact on
conversion of government securities, evaluation of transactions under new
accounting pronouncements, inflation, market risks and controls and procedures.
These forward-looking statements are further qualified by important factors that
could cause actual results to differ materially from those in the
forward-looking statements. These factors include, without limitation, changing
market and regulatory conditions, actual clinical results of our trials, the
impact of competitive products and pricing, the
21
FDA approval and market acceptance of our products, the maintenance of our
patent portfolio and ability to obtain competitive levels of reimbursement by
additional third-party payors, and other risks noted in our SEC filings from
time to time, including our Form 10-K for the period ending December 31, 2003,
none of which can be assured.
22
PART II - OTHER INFORMATION
Items 1, 3, and 5.
None.
Item 2. Changes in Securities and Use of Proceeds.
i) February 2004 Private Placement - On February 27, 2004, DUSA
entered into definitive agreements with certain new and existing
institutional and other accredited investors for the private
placement of 2,250,000 shares of our common stock at a purchase
price of $11.00 per share resulting in gross proceeds to DUSA of
$24,750,000. DUSA granted the investors the right to purchase up to
an aggregate of an additional 337,500 shares of common stock at
$11.00 per share which were exercised on April 14, 2004. Offering
costs incurred as of June 30, 2004 in connection with the placement
were $1,907,952, of which $1,707,750 consisted of the placement
agent's commission and non-refundable retainer paid in the form of
135,000 shares of common stock calculated at the offering price and
an additional 20,250 shares issued with respect to the exercise of
the additional investment rights. DUSA relied on Rule 506
promulgated under the Securities Act of 1933 in selling these
shares. DUSA engaged in due diligence to confirm that all
purchasers of the common stock were accredited investors.
DUSA will use the proceeds from the sale of the securities to
expand its sales force and for general working capital purposes,
including research and development activities.
Item 4. Submission of Matters to a Vote of Security Holders
Matters submitted to a vote of security holders of the Corporation at the Annual
Meeting of Shareholders held June 10, 2004 included the election of six (6)
directors, the ratification of the selection of Deloitte and Touche LLP as the
independent auditors for the Corporation for 2004, and an amendment to the
Omnibus Plan of 1996, as amended (the "Plan") to increase the number of shares
available for Awards under the Plan.
a) The following persons were elected to serve as directors of the
Corporation:
Votes Cast Votes Cast Broker
For Against Abstained Non-votes
---------- ---------- --------- ---------
D. Geoffrey Shulman 13,813,026 335,299 -0- -0-
John H. Abeles 13,830,526 317,799 -0- -0-
David Bartash 13,813,026 335,299 -0- -0-
Jay Haft 13,808,726 339,599 -0- -0-
Richard C. Lufkin 13,813,026 335,299 -0- -0-
Magnus Moliteus 13,830,526 317,799 -0- -0-
23
b) Shareholders ratified the selection of Deloitte & Touche LLP as the
independent auditors for the Corporation for 2004 as follows:
Votes Cast Votes Cast Broker
For Against Abstained Non-votes
---------- ---------- --------- ---------
Deloitte & Touche LLP 14,127,204 12,319 8,802 -0-
c) Shareholders ratified the amendment to the Plan increasing the number
of shares reserved for issuance of Awards under the Plan from 2,753,328
to 3,343,874 shares as follows:
Votes Cast Votes Cast Broker
For Against Abstained Non-votes
---------- ---------- --------- ---------
7,463,716 1,809,700 -0- -0-
Item 6. Exhibits and Reports on Form 8-K.
i) Exhibits
a) Exhibit 10(a) - Amended and Restated Purchase and Supply
Agreement between Registrant and National Biological
Corporation, effective as of June 21, 2004, portions of which
have been omitted as confidential pursuant to a request for
confidential treatment pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934 and Rule 406 of the Securities
Act of 1933.
b) Exhibit 31(a) - Rule 13a-14(a)/15d-14(a) Certification of the
Chief Executive Officer.
c) Exhibit 31(b) - Rule 13a-14(a)/15d-14(a) Certification of the
Chief Financial Officer.
d) Exhibit 32(a) - Certification of the Chief Executive Officer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002; and
e) Exhibit 32(b) - Certification of the Chief Financial Officer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
f) Exhibit 99(a) - Press Release dated August 10, 2004
ii) Forms 8-K
a) Form 8-K, dated April 14, 2004 and filed April 15, 2004,
reporting sales results for the quarter ended March 31, 2004
and participation in the 2004 Annual Meeting of the American
Society of Laser Medicine and Surgery in Dallas, Texas.
24
b) Form 8-K, dated and filed April 15, 2004, reporting that on
April 14, 2004 DUSA received exercise notices relating to the
exercise of additional investment rights to purchase 337,500
shares of its common stock at a price of $11.00 per share.
c) Form 8-K, dated and filed May 4, 2004, reporting that DUSA's
registration statement on Form S-3 with respect to the
2,587,500 shares issued to investors, and the 155,250 shares
issued to the placement agent as commissions and
non-refundable retainer, in connection with the recent private
placement, was declared effective.
d) Form 8-K, dated and filed May 20, 2004, announcing (i) the
initiation of a Phase II clinical study using DUSA's
Levulan(R) Photodynamic Therapy for treatment of facial
photodamage, and (ii) the filing of a Post-Effective Amendment
to an existing Registration Statement on Form S-8 with the
SEC.
e) Form 8-K, dated and filed June 8, 2004, reporting DUSA's
initiation of a Phase II Pilot Study of Levulan PDT for the
treatment of High-grade Dysplasia in Barrett's Esophagus.
25
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DUSA Pharmaceuticals, Inc.
By: /s/ D. Geoffrey Shulman
---------------------------------
D. Geoffrey Shulman
President and Chief Executive Officer
(principal executive officer)
Date: August 10, 2004 By: /s/ Peter M. Chakoutis
---------------------------------
Peter M. Chakoutis
Vice President and Chief
Financial Officer (principal
financial officer) and Controller
(principal accounting officer)
EXHIBIT INDEX
10(a) Amended and Restated Purchase and Supply Agreement between Registrant
and National Biological Corporation, effective as of June 21, 2004,
portions of which have been omitted as confidential pursuant to a
request for confidential treatment pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934 and Rule 406 of the Securities Act of
1933.
31(a) Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer.
31(b) Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.
32(a) Certification of the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002; and
32(b) Certification of the Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.
99(a) Press Release dated August 10, 2004